Cu­ria nets con­tract for cannabi­noid can­di­date and taps a new pres­i­dent of man­u­fac­tur­ing

02 Aug 2022
endpts.com
The CD­MO Cu­ria, fresh off an ex­pan­sion a year ago, is scal­ing up man­u­fac­tur­ing for a can­di­date from an Aus­tralian biotech.
In­can­nex Health­care, a biotech cen­tered on pro­duc­ing cannabi­noid-based med­i­cines and psy­che­del­ic ther­a­pies, is us­ing Cu­ria Glob­al to fur­ther de­vel­op and man­u­fac­ture a GMP-grade in­haled drug prod­uct for the treat­ment of con­cus­sion and trau­mat­ic brain in­jury orig­i­nal­ly de­vel­oped by the biotech.
The can­di­date, dubbed IHL-216A, com­bines cannabid­i­ol and isoflu­rane to treat con­cus­sions and oth­er trau­mat­ic brain in­juries. The in­tent is to im­prove re­cov­ery time and de­crease the im­pact of the in­jury on the qual­i­ty of life.
As Cu­ria ex­pands, it will add API site in up­state New York; In bat­tle against food al­ler­gies, Al­ladapt to build site to prep for PhI­II tri­als
The deal with Cu­ria, for which fi­nan­cial de­tails were not dis­closed, will have the com­pa­ny scale up the fill-fin­ish man­u­fac­ture of IHL-216A in com­pli­ance with cGMP. Cu­ria will al­so gen­er­ate da­ta on the qual­i­ty and sta­bil­i­ty of the can­di­date to sup­port fu­ture reg­u­la­to­ry fil­ings.
The first man­u­fac­tured batch will be used in the Phase I clin­i­cal tri­al, which will com­mence once feed­back on the can­di­date’s de­vel­op­ment plan is re­ceived from the FDA, which is set to con­clude in Q3 2022.
Cu­ria nets con­tract for cannabi­noid can­di­date and taps a new pres­i­dent of man­u­fac­tur­ing
Preview
Source: Endpts
Steve Lichter
In ad­di­tion to the deal, Cu­ria has named a new pres­i­dent for its man­u­fac­tur­ing op­er­a­tion. The com­pa­ny is tap­ping Niall Con­don, ef­fec­tive im­me­di­ate­ly, as cur­rent pres­i­dent Steve Lichter re­tires. He’ll be re­spon­si­ble for the de­liv­ery of Cu­ria’s com­mer­cial man­u­fac­tur­ing ser­vices and prod­ucts, in­clud­ing APIs and oth­er drug prod­ucts.
“The CD­MO in­dus­try is dy­nam­ic, and Cu­ria is unique­ly po­si­tioned to serve cus­tomers with its in­no­v­a­tive port­fo­lio of so­lu­tions and prod­ucts span­ning R&D through man­u­fac­tur­ing. I’m look­ing for­ward to meet­ing its tal­ent­ed com­mu­ni­ty of col­leagues and mak­ing an im­pact for our cus­tomers and the pa­tients they serve,” Con­don said.
Con­don has ex­ten­sive ex­pe­ri­ence in the man­u­fac­tur­ing field as he re­cent­ly served as head of API and OSD man­u­fac­tur­ing at Vi­a­tris, which was formed through the merg­er of My­lan and Pfiz­er’s Up­john. Be­fore that, he was a se­nior vice pres­i­dent at Pfiz­er, where he helped build the Up­john Di­vi­sion. He al­so spent over 30 years at Pfiz­er in roles of in­creas­ing re­spon­si­bil­i­ty in man­u­fac­tur­ing and oth­er op­er­a­tions.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.